Peer Reviewed Studies L-Glutathione "Cancer and other Desease"
|
|
1 |
Chemotherapy, or phyto-chemotherapy kill cancer cells, glutathione helps protect healthy and cancerous cells from the process of apoptosis but does not protect them from the immune system. Glutathione blocks apoptosis, both chemotherapy and phyto-chemotherapy agents, by protecting the cell membrane. Glutathione should not be used with agents that promote apoptosis but can be used with pancreatic enzymes; pancreatic enzymes hydrolyze the chemical bonds of cancer cells.
Glutathione anticancer activity is promoted by increasing killer T cells, helper T cells and macrophages...see chart...Click here |
| 2 |
Glutathione deficiency contributes to oxidative
stress, which plays a key role in aging and the pathogenesis
of many diseases including cachexia, seizure, Alzheimer’s
disease, Parkinson’s disease, liver disease, cystic
fibrosis, sickle cell anemia, HIV, AIDS, cancer, heart attack,
stroke, and diabetes. New knowledge of the nutritional
regulation of GSH metabolism is critical for the development
of effective strategies to improve health and to treat
these diseases. J. Nutr. 134: 489–492, 2004...Click Here |
| 3 |
Thus, oral L-glutathione can be considered as a safe precursor of L-cysteine, because it generates
the amino acid slowly through the combined action of intestinal y-glutamyl transpeptidase
and a-dipeptidases. 2-Oxothiazolidine carboxylate is another safe precursor for L-glutathione
synthesis (Williamson & Meister, 198 1) because it generates L-cysteine slowly, i.e. through
the enzymic action of 5-oxoprolinase (EC 3.5.2.9).
The main fact reported here, i.e. that oral administration of L-glutathione increases the
intracellular levels of L-glutathione, may explain in part some results by other authors who have
observed that dietary L-glutathione supplementation reverses the age-associated decline in immune
response (Furukawa et al. 1987). Furthermore, since oral L-glutathione may be used to
protect the liver against, for instance, paracetamol overdosage, the facts reported here may
have practical importance...Click Here |
| 4 |
Glutathione S-transferase P1 polymorphism expression in tumor tissue as measured by immunohisto
Kaplan-Meier function for overall survival
among women treated for breast cancer, by
glutathione S-transferase P1 polymorphism Ile105Val genotype, according to race and
estrogen receptor status.
Glutathione S-transferase P1 polymorphism and breast cancer survival
chemistry predicts poorer prognosis for cancers of several sites, e.g.,
ovary (12, 13). Studies of glutathione S-transferase P1 polymorphism enzyme expression and prognosis in
women treated for breast cancer (14 –18), however, have not provided
consistent evidence of a relationship. Our finding of a survival difference
in women with breast cancer according to host constitutive
glutathione S-transferase P1 polymorphism genotype is biologically plausible, even in the absence of a
relationship between breast tumor glutathione S-transferase P1 polymorphism expression and prognosis.
Among individuals with similar levels of glutathione S-transferase P1 polymorphism expression in tumor...Click Here |
| 5 |
Killer T cells destroy cancer cells / Cachexia Cancer Patients have low Glutathione levels
The combination of abnormally low
plasma cystine and glutamine levels, low natural killer
T cell activity, increase skeletal muscle wasting or muscle
fatigue, and increased rates of urea production defines
a complex of abnormalities that is tentatively
called “low cystine and glutamine syndrome.” These symptoms are
found in patients with HIV infection, cancer, major
injuries, sepsis, Crohn’s disease, ulcerative colitis,
chronic fatigue syndrome, and to some extent in
overtrained athletes...Click Here |
| 6 |
Killer T Cells Indused By Glutathione
Suppression of a Squamous Cell Carcinoma (SCC)-related Serpin, SCC Antigen,
Inhibits Tumor Growth with Increased Intratumor Infiltration of Natural
Killer Cells...Click Here |
|
